The long-term trend of the EPS is an important number as it indicates the present value of Cue Biopharma. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol CUE here. Growth in EPS is an important measure of administration performance because it shows how much money Cue Biopharma is making for it’s investors or shareholders.

Cue Biopharma is part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Daniel R. Passeri. Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.

Previous Intraday Performance:

The CUE shares had a previous change of -4.24% which opened at 5.40 and closed at 5.20. It moved to an intraday high of 5.43 and a low of 5.15.

SeekingAlpha:  Key events next week – healthcare

Historical Performance:

Over the last five trading days, CUE shares returned 0.39% and in the past 30 trading days it returned 12.07%. Over three months, it changed -15.03%. In one year it has changed -62.02% and within that year its 52-week high was 17.99 and its 52-week low was 4.16. CUE stock is 25.00% above its 52 Week Low.

Our calculations result in a 200 day moving average of 8.82 and a 50 day moving average of 5.23. Right now, CUE stock is trading -41.01% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Key events next week – healthcare


The company has a market cap of $104.7m with 20.1m shares outstanding and a float of 18.4m shares. Trading volume was 66,359 shares and has experienced an average volume of 91,356 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Cue Biopharma was -1.13 which ended on 31st of December 2017.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.62
06-30-2018:  -0.36
03-31-2018:  -0.37

Indicators Also to Watch:

Based on the latest filings, there is 8.50% of insider ownership and 24.30% of institutional ownership.

I calculated the beta to be 0.74

PR Newswire:  Flagstar Initiates Dividend and $50 Million Share Repurchase

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -172.65%, return on assets is -148.58%, price-to-sales is 134.64 and price-to-book is 2.77.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here